Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells

2006 ◽  
Vol 96 (08) ◽  
pp. 196-201 ◽  
Author(s):  
Xiaofeng Jiang ◽  
Yan Guo ◽  
Michael Bromberg

Summary Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with factorVIIa (FVIIa).TF is constitutively expressed ina variety of tumor cells and has been shown to playa role in cellular signaling and tumor progression. In this study, we investigated the effect of TF-FVIIa mediated signaling on apoptosis in human breast cancer cells. Apoptosis was induced by prolonged serum starvation and studied using the Adr-MCF-7 cell line, which has high endogenous TF expression. Treatment of the cells with the combination of FVIIa (10 nM) and FX (150 nM), reduced apoptosis by nearly 50% compared with untreated, control cells using an ELISA that detects histone-DNA fragments. In contrast, FVIIa (10 nM) alone did not significantly prevent apoptosis. Pretreatment of the Adr-MCF-7 cells with hirudin, a specific thrombin inhibitor, did not inhibit the anti-apoptotic effect of the combination of FVIIa and FX, whereas this effect could be abrogated by inhibition of phosphorylation of either p44/42 mitogen-activated protein kinase (MAPK) or protein kinaseB (PKB/Akt). In addition, treatment of theAdr-MCF-7 cells with the combination of FVIIa and FX led to a 30-50% increase in the level of the anti-apoptotic protein, survivin, compared with untreated cells usingWestern blot analysis. These results indicate that formation of TF-FVIIa-FXa complex prevents apoptosis in breast cancer cells by a thrombin-independent pathway. Moreover, the anti-apoptotic effect of this signaling pathway involves phosphorylation of both p44/42 MAPK and PKB/Akt and might be mediated in part by an increase in cell survivin levels.

2020 ◽  
pp. 1-5
Author(s):  
Oyindamola Vivian Ojulari ◽  
Jong-Beom Chae ◽  
Seul Gi Lee ◽  
Kyoungjin Min ◽  
Taeg Kyu Kwon ◽  
...  

2003 ◽  
Vol 17 (10) ◽  
pp. 2002-2012 ◽  
Author(s):  
Olga A. Sukocheva ◽  
Lijun Wang ◽  
Nathaniel Albanese ◽  
Stuart M. Pitson ◽  
Mathew A. Vadas ◽  
...  

Abstract Current understanding of cytoplasmic signaling pathways that mediate estrogen action in human breast cancer is incomplete. Here we report that treatment with 17β-estradiol (E2) activates a novel signaling pathway via activation of sphingosine kinase (SphK) in MCF-7 breast cancer cells. We found that E2 has dual actions to stimulate SphK activity, i.e. a rapid and transient activation mediated by putative membrane G protein-coupled estrogen receptors (ER) and a delayed but prolonged activation relying on the transcriptional activity of ER. The E2-induced SphK activity consequently activates downstream signal cascades including intracellular Ca2+ mobilization and Erk1/2 activation. Enforced expression of human SphK type 1 gene in MCF-7 cells resulted in increases in SphK activity and cell growth. Moreover, the E2-dependent mitogenesis were highly promoted by SphK overexpression as determined by colony growth in soft agar and solid focus formation. In contrast, expression of SphKG82D, a dominant-negative mutant SphK, profoundly inhibited the E2-mediated Ca2+ mobilization, Erk1/2 activity and neoplastic cell growth. Thus, our data suggest that SphK activation is an important cytoplasmic signaling to transduce estrogen-dependent mitogenic and carcinogenic action in human breast cancer cells.


1993 ◽  
Vol 215 (3) ◽  
pp. 671-676 ◽  
Author(s):  
Noriyoshi KIDA ◽  
Tomoaki YOSHIMURA ◽  
Haruo TAKAHASHI ◽  
Seiji NAGAO ◽  
Yoshinori NOZAWA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document